Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...

In this article, we are going to take a look at where Flotek Industries, Inc. (NYSE:FTK) stands against other energy infrastructure stocks that are skyrocketing. In January 2024, the Biden ...

Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for flatexDEGIRO (XTRA:FTK) from Neutral to Outperform. As of December 23, 2024, the average one-year price target ...